Open Journal Systems

Coronavirus and cardiovascular system

Dres Sofía Noria, Juan Pablo Bachini, María Victoria Ramos

Article ID: 1905
Vol 2, Issue 2, 2021

DOI: https://doi.org/10.54517/ccr.v2i2.1905
VIEWS - 32 (Abstract)

Abstract

The current pandemic caused by the new coronavirus (SARS-CoV-2) has been the focus of worldwide health concern since its appearance. Its high transmissibility associated with the absence of an effective treatment implies a hard impact in the research area. Reports on atypical forms of presentation, associated risk factors and drugs tested to reduce morbidity and mortality saturate the media. The cardiological community is actively involved, since cardiovascular manifestations are frequent and varied, and an increased risk of poor outcome has been observed in individuals with previous cardiovascular disease. The aim of the review is to provide the available evidence on this topic, with the caveat that the information is dynamic.

Keywords

SARS-COV-2; COVID-19; cardiovascular disease

Full Text:

PDF

References

1. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020. pii: S0735-1097(20)34637-4. doi: 10.1016/j. jacc.2020.03.031.

2. Case viewer [Internet]. Montevideo: Sistema Nacional de Emergencia SINAE;2020 [accessed 24 Apr 2020]. Available at: https://www.gub.uy/sis- tema-nacional-emergencias/

3. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin JK, Horn E, et al. The variety of cardiovas-cular presentations of COVID-19. Circulation 2020. doi: 10.1161/CIRCULATIONAHA.120.047164.

4. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) withafocuson congenital heart disease. Inter J Cardiol. 2020. doi: 10.1016/j.ijcard.2020.03.063.

5. AkhmerovA, Marbán E. COVID-19 and the Heart. Circulation Research [Internet] 2020 Apr [accessed 24 Apr 2020]. Available from: https://www.ahajour- nals.org/doi/10.1161/CIRCRESAHA.120.317055.

6. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coro-navirus (COVID-19) [Internet]. Bethesda: Stat Pearls; 2020 [accessed 24 Apr 2020]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.

7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factorsfor mortality of adult inpa-tients with COVID-19 in Wuhan, China: a retro-spective cohort study. Lancet. 2020; 395(10229): 1054-62. doi: 10.1016/S0140-6736(20) 30566-3. Erratum: Lancet.2020;395(10229): 1038. doi: 10.1016/ S014040-6736(20)30606-1.

8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/ ja-ma.2020.1585.

9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5. Erratum: Lancet. 2020;395(10223):496. doi: 10.1016/S0140-6736(20)30252-X.

10. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA March 25, 2020. doi: 10.1001/jamacar- dio.2020.0950. [Epub ahead of print].

11. Wu Z, McGoogan JM. Characteristics of and Im-portant Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Abstract of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323 (13):1239-42. doi:10.1001/jama.2020.2648.

12. Libby P, Ridker PM, Hansson GK, Leducq Transat-lantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-38.

13. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-60. doi: 10.1038/s41569-020-0360-5.

14. McMurray J, Pfeffer M, Solomon S. Ren-in-angio-angio- tensin-aldosterone system inhibi-tors in patients with COVID-19. N Engl J Med. 2020;382(17). doi: 10. 1056/NEJMsr2005760.

15. Zhang P, Zhu L, Cai J,Lei F, Quin J, Xie J, et al. As-sociation of inpatient use of angiotensin converting enzyme inhibitors and Angiotensin II recep-tor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circu-lation Research [Internet] 2020 Apr [accessed 24 Apr 2020]. Available from: https://www.ahajournals.org/doi/10. 1161/CIRCRESAHA.120.317134

16. Frankie Tam Ch, Cheung K, Lam S, Wong A, Yung A, Sze M, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circulation: Cardiovascular Quality and Outcomes. 2020;13(4):e006631.

17. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36(1):78-80. doi: 10.5144/ 0256-4947.2016.78.

18. Zeng JH, Liu YX, Yuan J, Wang F, Wu W, Li J, et al. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights. Pre- prints.org; 2020. doi:10.20944/preprints202003.0180.v1.

19. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020. doi: 10.1016∕j.jacc.2020.03.031 [in press].

20. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020. pii: ehaa231. doi: 10.1093/eurheartj/ehaa231.

21. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in pa-tients with COVID-19. A Case Series. N Engl J Med. 2020. doi:10.1056/NEJMc2009020.

22. Romaguera R, Cruz-González I, Jurado-Román A, Ojeda S, Fernández-Cisnal A, Jorge-Pérez P, et al. Considerations on the invasive approach to is-chemic and structural heart disease during the COVID-19 coronavirus outbreak. Consensus doc-ument of the Association of Interventional Cardi-ology and the Association of Ischemic Heart Disease and Acute Cardiovascular Care of the Spanish So-ciety of Cardiology. REC Interv Cardiol. 2020. doi:10.24875/RECIC.M20000119

23. Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, et al. Management of acute my-ocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. 2020. doi: 10.1016/j. jacc.2020.04.039.

24. Lazzerini P, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: Mind the Gap! Circulation 2020. doi: 10.1161/CIRCULA- TIO-NAHA.120.047293

25. Vidovich MI. Transient Brugada-like ECG pattern in a patient with coronavirus disease 2019. JACC Case Rep. 2020. doi: 10.1016/j.jaccas.2020.04.007.

26. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017; 38(22):1717-27. doi: 10.1093/eurheartj/ehw208.

27. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for pre-vention, antithrombotic therapy, and Follow-up. J Am Coll Cardiol. 2020. doi: 10.1016/j.jacc. 2020.04.031 [Journal Pre- proof].

28. Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflam- matory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020. [Epub ahead of print].

29. Helms J, Tacquard C, Severac F, Leonard-Lo- rant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients in severe SARS-CoV-2 in-fection: a multicenter prospective cohort study. In-tensive Care Med. 2020. doi: 10.1007/s00134-020- 06062-x.